[6-K] UTime Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

UTime Limited (WTO) furnished a Form 6-K noting it issued a press release on its ongoing exploration in health data analysis, particularly the potential application of artificial intelligence technologies. The filing identifies the press release as Exhibit 99.1. This is an informational update about the company’s R&D focus area and does not describe a transaction or financing. The report is signed by Chief Executive Officer Hengcong Qiu.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission file number 001-40306

UTIME LIMITED

7^th Floor Building 5A

Shenzhen Software Industry Base

Nanshan, Shenzhen

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On November 3, 2025, UTime Limited (the “Company”) issued a press release outlining its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies.. A copy of the press release is attached hereto as Exhibit 99.1.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated November 3, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UTIME LIMITED
Dated: November 3, 2025	By:	/s/ Hengcong Qiu
	Name:	Hengcong Qiu
	Title:	Chief Executive Officer
		(Principal Executive Officer)